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Abstract
Background: Influenza is a respiratory disease that seriously threatens human health. In fact, influenza virus itself
does not make critical contribution to mortality induced by influenza, but “cytokine storm” produced by the
excessive immune response triggered by the virus can result in inflammatory reaction of lung tissues and fatal lung
tissue injury, and thus increase influenza mortality. Therefore, besides antiviral drugs, immunosuppression drugs
should also be included in infection treatment.
Presentation of the hypothesis: Complement is the center of inflammatory reaction. If complement system is
over activated, the body will have strong inflammatory reaction or tissue injury, resulting in pathological process.
Many studies have proved that, inflammatory injury of lung tissues caused by influenza virus is closely related to
complement activation. Therefore, inhibiting complement activation can significantly reduce inflammatory injury in
lung tissues. As complement is both a physiological defense and pathological damage medium, systematic
inhibition may result in side effects including infection. Therefore, we design targeting complement inhibitors for
complement activation sites, i.e. with CR2 as targeting vector, complement inhibitors like CD59 and Crry are
targeted to inflammatory sites to specially inhibit the complement activation in local injury, thus local inflammatory
reaction is inhibited.
Testing the hypothesis: CR2-CD59 and CR2-Crry targeting complement inhibitors are fusion-expressed, and their
biological activity is examined via in vivo and in vitro tests. CR2 targeting complement inhibitors are used to treat
mouse influenza viral pneumonia model, with PBS treatment group as the control. The survival and lung tissue
injury of the mice is observed and the effect of CR2 targeting complement inhibitors on pneumonia induced by
influenza virus is evaluated.
Implications of the hypothesis: CR2 targeting complement inhibitors are expected to be ideal drugs for viral
pneumonia.
Background
Influenza is an acute infectious disease caused by influ-
enza virus, with respiratory damage as main outcome. It
is epidemiologically characterized as rapid prevalence,
wide dissemination, acute incidence and huge hazard,
and is one of diseases that seriously threaten human
health. A report by World Health Organization shows
that there are 3-5 million severe influenza cases and
250,000-500,000 mortality every year [1]. Influenza pan-
demias happened for four times in the 20
th century. The
Spanish flu in 1918 was the most serious one. It claimed
50 million lives at least, even more than the mortality in
Fist World War [2]. More than 10,000 people died of
H1N1 flu in 2009 [3]. Influenza produces a large num-
ber of morbidity and mortality, and also results in great
economic loss and social burden.
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reason for patient mortality. Oda T et al. pointed out in
1989 that symptoms of influenza are inflammatory
injury as a result of immune activation by influenza
virus, instead of being directly induced by influenza
virus [4]. Immune system is activated in case of invasion
by influenza virus. Studies have shown that when influ-
enza virus invades human cells, cytokines and chemota-
tic factors are stimulated to produce many inflammatory
proteins, which helps to defense virus [5-8]. Chemotatic
factors and cytokines are the messengers of immune
system, and play an important role in coordination and
regulation of immune response. When influenza virus
enters lung tissues, the immune system will lose control
and make over reaction by releasing too many cytokines
like “cytokines storm” [9,10]. Immune system running
out of control will induce severe inflammation, and
results in indirect hazard, which may induce inflamma-
tion again, damage the lung, and finally result in fatal
pneumonia and acute respiratory tract infection syn-
dromes. This indicates that influenza patients require
both antiviral drugs and immunosuppression drugs [10].
Studies have shown that inflammatory injury of lung tis-
sues is the main fatal reason for influenza A (H1N1)
and bird flu, SARS, septicemia, aspiration pneumonia
and liver infection induced by anthrax Bacillus as well
[10-13].
Presentation of the hypothesis
Complement is the center of inflammatory reaction
Complement is an important and conservative system
for natural immune, and provides pathways for rapid
and effective elimination of invasive micro-organisms
[14,15]. It is a “bridge” between natural immune and
acquired immune. Besides direct immune mechanism,
complement can also release many types of small mole-
cular fragments which have broad biological effects,
such as chemotaxis of neutrophils and lymphocytes,
phagocytosis, and participa t i o ni nr e g u l a t i n gi m m u n e
response of cells and body fluid. In addition, Comple-
ment system is also an important medium for inflamma-
tion and immune reaction, and poses great potential
threat to the body. If complement system is over acti-
vated, many complement components will be consumed,
and reduce the anti-infection ability of the body; many
active substances derived from the activation will induce
severe inflammatory reaction or tissue injury, resulting
in pathological process [16]. For example, complement
activation can produce inflammatory media including
C2a, C3a, C4a and C5a. C2a has kinin-like function, and
can expand small vessels and improve permeability; C3a,
C4a and C5a have anaphylatoxin function, and can
degranulate mast cells and basophils, release vasoactive
mediators and induce inflammatory reaction; C3a, C5a
and C5b67 have chemotaxis function, and can attract
inflammatory cells to concentrate and migrate toward
the inflammatory region activated by the complement,
and thus increase inflammatory reaction.
CR2 is the central molecule for the immune response
regulation by complement system. Split products of C3
molecules includes C3dg, iC3b, C3d and C3b, which are
deposited on the activating cell surface and are the spe-
cific ligands for CR2 molecules. So CR2 is a good
choice as a tarteting vector for delivery of complement
inhibitors such as Crry and CD59 to sites of inflamma-
tion induced by complement activation. Many studies
have indicated that CR2 targeting complement inhibi-
tors can significantly mitigate inflammatory reaction in
local sites [17,18]. CD59 and Crry are important com-
plement regulatory protein and the ideal complement
inhibitor. CD59 can interfere the combination of C7, C8
with C5b-6 complex and inhibite the formation of
membrane attack complex, MAC. Crry can block the
complement activation by inhibite the activity of C3/C5
convertase.
Influenza viral lung injury and complement activation
Many studies have proved that excessive inflammatory
injury in lung tissues induced by influenza virus infec-
tion is closely related to complement activation. Com-
plement activation can affect influenza virus-specific
immune response in the lung [19,20]. After being
infected by influenza virus, C3-deficient mice see signifi-
cant decrease of T-cell reaction, and complement activa-
tion plays an important role in T-cell activation or
recruitment [21,22]. Martin has found that C3a and C5a
can induce neutrophil migration in the lung infected by
influenza virus [23]. All the above studies show that
complement activation following influenza virus infec-
tion can significantly influence pulmonary infiltration
and lung injury degree. Hohenthal U and Nuutila J
found that complement receptors have strong expres-
sion in influenza viral pneumonia [24,25]. Kase T found
that human MBL can directly or indirectly remove influ-
enza virus particles and inhibit viral transmission
through complement activation and opsonization [26].
Through coupling with influenza antigen HA, C3d can
increase the level of anti-influenza virus HA antibody,
reduce the activation threshold of B-cell and improve
the intensity of immune response [27,28]. M. Paula
Longhi et al. found that CD59a-deficient mice (Cd59a
(-/-)) inflected with influenza virus have more serious
pneumonia than wild-type, with more significant pul-
monary hemorrhage and leukocytic infiltrate, neutrophil
and lymphocyte aggregation, lung cell fibrosis and CD4
+
T-cell activation; after injection of complement inhibi-
tors, Cd59a(-/-) mice have improved lung inflammatory
reaction and significant neutrophil infiltration decrease
[29].
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The above studies indicate that through inhibiting com-
plement activation, excessive inflammatory reaction in
lung tissues induced by influenza can be inhibited, and
as a result, lung tissue injury can be mitigated and the
mortality can be reduced. As complement is both a phy-
siological defense and a pathological damage medium, it
functions as a double-edged sword. Systematic comple-
ment inhibition may result in potential side effects
including infection. Therefore, we design targeting com-
plement inhibitors for complement activation sites with
CR2 as targeting vector, complement inhibitors like
CD59 and Crry are targeted to inflammatory sites to
specially inhibit the complement activation in the local
injury, thus local inflammatory reaction is inhibited,
without side effects caused by systematic inhibition.
Testing the hypothesis
CR2 gene was respectively linked to genes of comple-
ment inhibitors including CD59 and Crry (CR2-CD59,
CR2-Crry), and then is fusion expressed in CHO cells
and purified from culture supernatant by affinity chro-
matography. Biological activity of CR2 targeting comple-
ment inhibitors is examined with in vivo and in vitro
tests. BALB/c mice are applied to inhale mouse lung-
adapted virulent strain of H1N1 influenza A virus (A/
fm/1/47) via nose to duplicate influenza pneumonia
model in mice. The mice are then treated with CR2 tar-
geting complement inhibitors, with PBS treatment
group as the control. Final work is to observe the survi-
val and lung tissue injury of the mice, and evaluate the
effect of CR2 targeting complement inhibitor on influ-
enza viral pneumonia.
Implication of the hypothesis
An effective CR2 targeting complement inhibitor can
reduce the mortality, significantly improve clinical symp-
toms (decreased weight, lung index and hemagglutina-
tion titer) and lung tissue inflammatory injury of virus-
infected model group. Therefore, CR2 targeting comple-
ment inhibitor is expected to be an ideal drug for viral
pneumonia.
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